Halozyme Therapeutics(NASDAQ) HALO
| Metric | Price | Date |
|---|---|---|
| Last close | USD 81.93 | 2026-07-24 |
| Period | Price return | Price at period start | Period start date |
|---|---|---|---|
| 1 week | +5.29% | USD 77.81 | 2026-07-17 |
| 1 month | +15.15% | USD 71.15 | 2026-06-24 |
| 3 month | +25.35% | USD 65.36 | 2026-04-24 |
| Year to date | +21.74% | USD 67.30 | 2025-12-31 |
| 1 year | +39.41% | USD 58.77 | 2025-07-24 |
| 3 year | +91.38% | USD 42.81 | 2023-07-25 |
| 5 year | +91.02% | USD 42.89 | 2021-07-23 |
| Since inception | +1,874.22% | USD 4.15 | 2004-03-12 |
Halozyme Therapeutics Financials at a Glance
Market Cap
Revenue (TTM)
Net Income (TTM)
EPS (TTM)
P/E Ratio
Dividend
Beta (Volatility)
Dividend
Beta (Volatility)
Price
Volume
Open
Price
Volume
Open
Previous Close
Daily Range
52-Week Range
Estimated Earnings Date
Dividend
Beta (Volatility)
Price
Volume
Open
Previous Close
Daily Range
52-Week Range
Estimated Earnings Date
HALO News
HALO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Halozyme Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
423
CEO
Helen I. Torley, MD
Website
www.halozyme.comHeadquarters
San Diego, CA 92121, US
HALO Financials
Key Financial Metrics (TTM)
Gross Margin
Operating Margin
Net Income Margin
Return on Equity
Return on Capital
Return on Assets
Earnings Yield
Dividend Yield
Payout Ratio
Stock Overview
Market Cap
Shares Outstanding
Volume
Avg. Volume
Financials (TTM)
Gross Profit
Operating Income
EBITDA
Operating Cash Flow
Capital Expenditure
Free Cash Flow
Cash & ST Invst.
Total Debt
Halozyme Therapeutics Performance Analysis
| Fiscal year | Period end | Revenue | YoY growth |
|---|---|---|---|
| 2022 | 2022-12-31 | USD 660,116,000 | 48.9% |
| 2023 | 2023-12-31 | USD 829,253,000 | 25.6% |
| 2024 | 2024-12-31 | USD 1,015,324,000 | 22.4% |
| 2025 | 2025-12-31 | USD 1,396,611,000 | 37.6% |
| Fiscal quarter | Period end | QoQ growth |
|---|---|---|
| Q2 | 2025-06-30 | 23.0% |
| Q3 | 2025-09-30 | 8.8% |
| Q4 | 2025-12-31 | 27.5% |
| Q1 | 2026-03-31 | -16.6% |
| Fiscal year | Period end | Diluted EPS | YoY growth |
|---|---|---|---|
| 2022 | 2022-12-31 | USD 1.44 | -47.6% |
| 2023 | 2023-12-31 | USD 2.10 | 46.0% |
| 2024 | 2024-12-31 | USD 3.43 | 63.5% |
| 2025 | 2025-12-31 | USD 2.56 | -25.5% |
| Fiscal quarter | Period end | QoQ growth |
|---|---|---|
| Q2 | 2025-06-30 | 43.0% |
| Q3 | 2025-09-30 | 7.5% |
| Q4 | 2025-12-31 | -183.9% |
| Q1 | 2026-03-31 | 201.7% |
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
+42.2%
Gross Profit
+34.9%
Gross Margin
N/A
Market Cap
N/A
Market Cap/Employee
N/A
Employees
N/A
Net Income
+27.1%
EBITDA
+30.1%
Quarterly Fundamentals
Total Cash
-57.4%
Total Debt
+42.3%
Accounts Receivable
+50.3%
Inventory
-5.7%
Long Term Debt
+28.4%
Short Term Debt
N/A
Return on Assets
N/A
Return on Invested Capital
N/A
Free Cash Flow
+15.0%
Operating Cash Flow
+16.8%